Acurx Pharmaceuticals receives FDA conditional acceptance for ibezapolstat brand name CIFBEZY
Acurx Pharmaceuticals closed at $1.6500 on August 17, up 18.28% from a previous close of $1.3950, on dollar volume of $1,796,725 across 4,593 trades. The move came after the company released two announcements: FDA conditional acceptance of the proposed brand name for its lead